Emily Field's Stock Ratings

Barclays Analyst

Emily Field is an analyst at Barclays. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/02/2025

Overall Average Return

10.5%

Smart Score

Overall Average Return Percentile

64th

Number of Ratings

6

		Buy Now								Get Alert
01/23/2025	GLPG	Buy Now	Galapagos	$24.77	—	Emily Field53%	—	Downgrade	Equal-Weight → Underweight	Get Alert
11/05/2021	GSK	Buy Now	GSK	$37.42	—	Emily Field53%	—	Upgrade	Underweight → Equal-Weight	Get Alert
10/19/2021	ARGX	Buy Now	argenx	$567.09	—	Emily Field53%	—	Upgrade	Equal-Weight → Overweight	Get Alert
12/06/2018	GSK	Buy Now	GSK	$37.42	—	Emily Field53%	—	Downgrade	Overweight → Equal-Weight	Get Alert
09/16/2013	GSK	Buy Now	GSK	$37.42	—	Emily Field53%	—	Downgrade	Overweight → Equal-Weight	Get Alert
01/29/2013	GSK	Buy Now	GSK	$37.42	—	Emily Field53%	—	Upgrade	Equal-Weight → Overweight	Get Alert

Recent Analyst Stock Rating News

Ricky Williams And Wellness Experts Discuss Strategies For Cannabis Patient-Centric Care

Leaders explore patient access and loyalty in the wellness cannabis market, challenges, adult-use impacts, and more at Benzinga's CCC

The Rise Of Female Leadership In Cannabis: Top Executives Share Their Insights

On International Women's Day, the cannabis industry stands as a testament to the significant strides made towards gender inclusivity and leadership diversity. This dynamic sector, known for its rapid growth and evolving landscape, has become a platform for women leaders to innovate, inspire and advocate for a more equitable space.

20 Most Influential Women In The Cannabis Industry And The Secret To Meet Them In Person In 2024

To celebrate International Women's Day, let's shine a light on the women making strides in cannabis — a field historically dominated by men.

Charles Koch-Backed Group Pulls Plug Nikki Haley's Campaign Funding, But Warns Of 'Irreparable Damage' If Trump Becomes GOP Nominee

Americans For Prosperity Action (AFP Action) has decided to cease funding Nikki Haley's bid for the Republican nomination.

Decoding Success: Hazar Orhon's Revolutionary Approach To Finance Strategy

"In a world awash with data, the true art lies in discerning the signal from the noise," declares Hazar Orhon, a Chartered Financial Analyst (CFA), reflecting on the current state of global finance. His wise words come from someone who has deciphered the complex narratives of finance and crafted his own way.

Sales Success Comes With Side Effects For Drug Maker BeiGene

Key Takeaways: Global sales of BeiGene’s anti-tumor drug zanubrutinib more than doubled to $308 million (2.22 billion yuan) in the quarter BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration

Tech Unicorn Fourth Paradigm relaunches IPO, Riding AI Wave

Key Takeaways: Beijing Fourth Paradigm, backed by big-name investors, provides platforms and services to help companies develop customized AI The company has completed 11 rounds of fund-raising since its launch, boosting its valuation by more than 100 times to $2.95 billion in six years 　 By Emily Chan

Innovative Drugs Soothe Fosun Pharma From Pain Of Fading Covid Vaccine

Key takeaways: Fosun Pharma’s net profit fell more than 20% last year due to a 30% drop in sales of its comirnaty Covid vaccine and investment losses The company’s innovative drugs generated more than 10 billion yuan during the year By Emily Chan

Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Product Approval Breathes New Life Into Boan Biotech IPO

Key Takeaways: Boan Biotechnology has filed for a Hong Kong listing, hoping to attract investors with its first-ever revenue following approval of its first two products With only 310 million yuan in cash, the company needs funds from the IPO to help fund commercialization of its new drugs By Emily Chan

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook